◎ Sugi Atlas

Atlas / Disease / Temporomandibular joint disorder

Temporomandibular joint disorder

disease
On this page

Also known as TMD

Summary

Temporomandibular joint disorder (MONDO:0005473) is a disease with 6 cohort genes (26 GWAS associations across 20 studies) and 215 clinical trials. Top therapeutic interventions include salicylic acid, hyaluronic acid, and benztropine.

At a glance

  • Cohort genes: 6
  • GWAS associations: 26
  • ClinVar variants: 1
  • Clinical trials: 215

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nametemporomandibular joint disorder
Mondo IDMONDO:0005473
EFOEFO:0005279
MeSHD013705
NCITC63709
SNOMED CT41888000
UMLSC0039494
MedGen21092
Is cancer (heuristic)no

Also known as: TMD

Data availability: 1 ClinVar variant · 26 GWAS associations (20 studies).

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › arthropathy › temporomandibular joint disorder

Related subtypes (23): transient arthropathy, synovial plica syndrome, hypermobility syndrome, Tietze syndrome, neurogenic arthropathy, Behcet syndrome arthropathy, ankylosis, bursitis, synovium neoplasm, hydrarthrosis, articular cartilage disorder, hemarthrosis, tenosynovitis, ganglion or cyst of synovium/tendon/bursa, spondyloarthropathy, arthritic joint disease, de Quervain disease, frozen shoulder, patellofemoral pain syndrome, secondary hypertrophic osteoarthropathy, shoulder impingement syndrome, crystal arthropathy, vertebral joint disorder

Subtypes (3): congenital temporomandibular joint ankylosis, primary condylar hyperplasia, temporomandibular joint dysfunction syndrome

Genetics & variants

GWAS landscape

26 GWAS associations across 20 studies. Top hits map to 14 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs5584552573e-12KL - STARD13C3.35
rs5307858465e-12RPLP0P7 - CDK7P1C2.71
rs5625676681e-11LINC02731G3.63
rs5465035721e-11FTH1P21 - LINC02272G3.98
rs1922159211e-11LIPFT1.58
rs1911259601e-11BNIP3 - JAKMIP3C3.55
rs5486587642e-11KRT17C4.37
rs1133714192e-11RNU7-14P - SUMO1P1G3.14
rs1925678722e-11DLC1G3.24
rs1859988062e-11LINC03093 - GFRA2T2.68
rs5738110693e-11NR1D2 - LINC00691G2.34
rs5348675593e-11SLC2A9T3.93
rs1906161584e-11LINC01271G2.98
rs1890390654e-11CYTH4 - ELFN2G2.83
rs2016876174e-11TGFBR1G3.6
rs5521169874e-11LRMDAC4.55
rs15315543e-08BAHCC1C1.47
rs754342553e-08SAP130 - Y_RNA?
rs734600754e-08DMDC1.78
rs602491664e-08B3GLCT - RXFP2T1.55
rs1393786202e-07TBC1D9?
rs732718653e-07ASS1P11 - RNU1-15PT1.79
rs1174580434e-07ZMAT3?
rs47941063e-06PPP1R9B - SGCAT1.3
rs100926334e-06SFRP1A3.8
rs8789628e-06TSPAN9C1.89

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90478289Verma A20245,123436,487Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478292Verma A20244,099439,649Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478288Verma A20241,744116,825Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480855Verma A20241,744116,825Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478291Verma A20241,396117,962Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480279Verma A20241,396117,962Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478287Verma A20241,03056,969Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST007619Smith SB20189992,031Genome-wide association reveals contribution of MRAS to painful temporomandibular disorder in males.
GCST90651586Liu TY2025952208,919Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478290Verma A202480857,605Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR2
Tier 3: regulatory0
Tier 4: intronic/intergenic24

MAF distribution

BucketVariants
common (>=0.05)6
low_freq (0.01-0.05)2
rare (<0.01)16
unknown2

Functional consequences

ConsequenceCount
intron_variant15
intergenic_variant9
3_prime_UTR_variant2

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs5584552571333074183C>T0intergenic_variantKL - STARD133e-12Tier 4: intronic/intergenic
rs5307858462157133082C>T0.001intergenic_variantRPLP0P7 - CDK7P15e-12Tier 4: intronic/intergenic
rs56256766811134040421G>A0intron_variantLINC027311e-11Tier 4: intronic/intergenic
rs5465035724156214776G>A0intergenic_variantFTH1P21 - LINC022721e-11Tier 4: intronic/intergenic
rs1922159211088672563T>C0.004intron_variantLIPF1e-11Tier 4: intronic/intergenic
rs19112596010132014724C>A0intergenic_variantBNIP3 - JAKMIP31e-11Tier 4: intronic/intergenic
rs5486587641741623764C>A,T0intron_variantKRT172e-11Tier 4: intronic/intergenic
rs1133714192053766889G>A0intergenic_variantRNU7-14P - SUMO1P12e-11Tier 4: intronic/intergenic
rs192567872813191336G>A0intron_variantDLC12e-11Tier 4: intronic/intergenic
rs185998806821309530T>C0.001intergenic_variantLINC03093 - GFRA22e-11Tier 4: intronic/intergenic
rs573811069324039843G>T0intron_variantNR1D2 - LINC006913e-11Tier 4: intronic/intergenic
rs53486755949881557T>C0.001intron_variantSLC2A93e-11Tier 4: intronic/intergenic
rs1906161582050319561G>A0.002intron_variantLINC012714e-11Tier 4: intronic/intergenic
rs1890390652237328721G>A,T0.001intron_variantCYTH4 - ELFN24e-11Tier 4: intronic/intergenic
rs201687617999149879G>A,T03_prime_UTR_variantTGFBR14e-11Tier 2: splice/UTR
rs5521169871076302032C>T0.001intron_variantLRMDA4e-11Tier 4: intronic/intergenic
rs15315541781406747T>C,G0.476intron_variantBAHCC13e-08Tier 4: intronic/intergenic
rs754342552128039772C>G,T0.05intergenic_variantSAP130 - Y_RNA3e-08Tier 4: intronic/intergenic
rs73460075X32265375G>C0.036intron_variantDMD4e-08Tier 4: intronic/intergenic
rs602491661331510764C>T0.188intergenic_variantB3GLCT - RXFP24e-08Tier 4: intronic/intergenic
rs1393786204140629925A>Gintron_variantTBC1D92e-07Tier 4: intronic/intergenic
rs73271865721359709C>T0.041intergenic_variantASS1P11 - RNU1-15P3e-07Tier 4: intronic/intergenic
rs1174580433178960958A>G3_prime_UTR_variantZMAT34e-07Tier 2: splice/UTR
rs47941061750160933T>A,C0.451intron_variantPPP1R9B - SGCA3e-06Tier 4: intronic/intergenic
rs10092633841266213G>A,T0.14intron_variantSFRP14e-06Tier 4: intronic/intergenic
rs878962123178113G>A,C,T0.05intron_variantTSPAN98e-06Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 conflicting classifications of pathogenicity

ClinVarVariant (HGVS)GeneClassificationReview
2273189NM_001290223.2(DOCK1):c.2012T>A (p.Phe671Tyr)DOCK1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
SGCAOrphanet:62Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3
DMDOrphanet:154Familial isolated dilated cardiomyopathy
DMDOrphanet:206546Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers
DMDOrphanet:777X-linked non-syndromic intellectual disability
DMDOrphanet:98895Becker muscular dystrophy
DMDOrphanet:98896Duchenne muscular dystrophy

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only5
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
SGCAHGNC:10805ENSG00000108823Q16586Alpha-sarcoglycangwas
SP4HGNC:11209ENSG00000105866Q02446Transcription factor Sp4gwas
TSPAN9HGNC:21640ENSG00000011105O75954Tetraspanin-9gwas
BAHCC1HGNC:29279ENSG00000266074Q9P281BAH and coiled-coil domain-containing protein 1gwas
DMDHGNC:2928ENSG00000198947P11532Dystrophingwas
DOCK1HGNC:2987ENSG00000150760Q14185Dedicator of cytokinesis protein 1clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
SGCAAlpha-sarcoglycanComponent of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
SP4Transcription factor Sp4Binds to GT and GC boxes promoters elements.
DMDDystrophinAnchors the extracellular matrix to the cytoskeleton via F-actin.
DOCK1Dedicator of cytokinesis protein 1Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility.

Protein-family classification

Druggable: 0 · Difficult: 4 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Scaffold/PPI25.8×0.129
Transcription factor22.8×0.237
Other/Unknown20.6×0.936

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
SGCAOther/UnknownnoCadg, Sarcoglycan_alpha/epsilon, Cadherin-like_sf
SP4Transcription factornoZnf_C2H2_type, Znf_C2H2_sf, Sp4-like
TSPAN9Other/UnknownnoTetraspanin_animals, Tetraspanin_EC2_sf, Tetraspanin/Peripherin
BAHCC1Scaffold/PPInoBAH_dom, BAH_sf, Tudor_BAHCC1
DMDTranscription factornoZnf_ZZ, WW_dom, Actinin_actin-bd_CS
DOCK1Scaffold/PPInoSH3_domain, ARM-type_fold, DOCK

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)6
unknown0

Top tissues across cohort

TissueCohort genes
apex of heart2
cerebellar cortex2
cerebellar hemisphere2
gastrocnemius1
hindlimb stylopod muscle1
cerebellar vermis1
germinal epithelium of ovary1
superficial temporal artery1
right hemisphere of cerebellum1
dorsal root ganglion1
skeletal muscle tissue of rectus abdominis1
trigeminal ganglion1
corpus callosum1
globus pallidus1
medial globus pallidus1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
SGCA190broadmarkerhindlimb stylopod muscle, gastrocnemius, apex of heart
SP4265ubiquitousmarkercerebellar vermis, germinal epithelium of ovary, superficial temporal artery
TSPAN9270ubiquitousmarkerapex of heart, cerebellar hemisphere, cerebellar cortex
BAHCC1190ubiquitousmarkerright hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
DMD295ubiquitousmarkertrigeminal ganglion, skeletal muscle tissue of rectus abdominis, dorsal root ganglion
DOCK1276ubiquitousmarkercorpus callosum, medial globus pallidus, globus pallidus

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
DMD2,479
DOCK12,085
SGCA1,132
TSPAN9966
SP4924
BAHCC1548

Intra-cohort edges

ABSources
DMDSGCAstring_interaction

Structural data

PDB: 2 · AlphaFold-only: 4 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
DMDP115326
DOCK1Q141851

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
TSPAN9O7595489.65
SGCAQ1658680.15
BAHCC1Q9P28140.51
SP4Q0244639.58

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 14. Enrichment computed across 6 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Formation of the dystrophin-glycoprotein complex (DGC)2205.8×4e-04SGCA, DMD
Non-integrin membrane-ECM interactions2102.9×9e-04SGCA, DMD
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases1271.9×0.015DOCK1
DCC mediated attractive signaling1237.9×0.015DOCK1
SRC activates STAT3 in a quantitative manner, through Cadherin-11 (CDH11), RAC1 and gp130 (IL6ST)1165.5×0.017DOCK1
Striated Muscle Contraction1102.9×0.023DMD
FCGR3A-mediated phagocytosis162.4×0.028DOCK1
Regulation of actin dynamics for phagocytic cup formation161.4×0.028DOCK1
RHOG GTPase cycle149.4×0.030DOCK1
VEGFA-VEGFR2 Pathway146.4×0.030DOCK1
RAC2 GTPase cycle142.3×0.030DOCK1
Factors involved in megakaryocyte development and platelet production122.1×0.048DOCK1
Extracellular matrix organization121.0×0.048SGCA
RAC1 GTPase cycle120.4×0.048DOCK1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
regulation of muscle system process13370.4×0.004DMD
regulation of cellular response to growth factor stimulus13370.4×0.004DMD
receptor diffusion trapping13370.4×0.004TSPAN9
muscle organ development266.7×0.004SGCA, DMD
cardiac muscle cell action potential11685.2×0.005DMD
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion1842.6×0.007DMD
peptide biosynthetic process1842.6×0.007DMD
regulation of skeletal muscle contraction1561.7×0.009DMD
mitocytosis1561.7×0.009TSPAN9
regulation of calcium ion transmembrane transport1421.3×0.010DMD
neutrophil homeostasis1306.4×0.012TSPAN9
synaptic signaling1306.4×0.012DMD
collagen-activated tyrosine kinase receptor signaling pathway1259.3×0.013TSPAN9
regulation of sodium ion transmembrane transport1210.7×0.015DMD
muscle cell development1187.2×0.015DMD
response to muscle stretch1153.2×0.017DMD
phagocytosis, engulfment1134.8×0.017DOCK1
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum1134.8×0.017DMD
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion1134.8×0.017DMD
muscle cell cellular homeostasis1129.6×0.017DMD
myoblast fusion1120.4×0.017DOCK1
motile cilium assembly1116.2×0.017DMD
regulation of mitochondrial membrane potential1108.7×0.017TSPAN9
maintenance of blood-brain barrier196.3×0.018DMD
regulation of heart rate193.6×0.018DMD
positive regulation of epithelial cell migration182.2×0.020DOCK1
cardiac muscle contraction180.2×0.020DMD
positive regulation of substrate adhesion-dependent cell spreading174.9×0.020DOCK1
regulation of postsynapse assembly168.8×0.021DOCK1
platelet aggregation167.4×0.021TSPAN9

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
RimegepantPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Benztropine, Celecoxib, Dexmedetomidine, Dextrose, Erenumab, Etanercept, Ibuprofen, Ketamine, Lidocaine, Nortriptyline, Onabotulinumtoxina, Sodium Chloride, Starch.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 6

Druggability breadth: 2 of 6 evidence-associated genes (33%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
SGCA00
SP400
TSPAN900
BAHCC100
DMD00
DOCK100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
DOCK11Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug6SGCA, SP4, TSPAN9, BAHCC1, DMD, DOCK1

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
SGCA0—
SP40—
TSPAN90—
BAHCC10—
DMD0—
DOCK11—

Clinical trials & evidence

Clinical trials

Clinical trials: 215.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified184
PHASE29
PHASE48
PHASE15
PHASE1/PHASE24
PHASE2/PHASE33
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06452134PHASE4NOT_YET_RECRUITINGEvaluation the Effect of Coenzyme Q10 on Tissue Healing Process in Patients Undergoing Wisdom Tooth Extraction
NCT07401745PHASE4ACTIVE_NOT_RECRUITINGOcclusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders
NCT03522207PHASE4TERMINATEDAccuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient
NCT04110587PHASE4COMPLETEDHyaluronic Acid Evaluation as Adjuvant to Temporomandibular Joint Arthroscopy
NCT04810429PHASE4COMPLETEDComparison of Temporomandibular Joint Arthroscopy With Botulinum Toxin Injection Versus Placebo
NCT05817162PHASE4UNKNOWNTemporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP
NCT06044974PHASE4COMPLETEDNd-YAG Laser Versus Epidermal Growth Factor For Myogenic Tempromandibular Disorder.
NCT06530745PHASE4COMPLETEDPRP vs HA Intra-articular Injections in TMDs
NCT05214924PHASE2/PHASE3ENROLLING_BY_INVITATIONEffectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management
NCT01706172PHASE2/PHASE3COMPLETEDTreatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection
NCT02908568PHASE2/PHASE3UNKNOWNStimulation of the Proprioceptive Trigeminocardiac Reflex
NCT06694532PHASE1/PHASE2RECRUITINGEffIcacy Between Arthrocentesis With High Versus Low Molecular Weight Hyaluronic Acid in Treatment of TMJ Disorders
NCT00001955PHASE2COMPLETEDStudy of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)
NCT00009594PHASE2COMPLETEDAlternative Medicine Approaches for Women With Temporomandibular Disorders
NCT00010621PHASE2COMPLETEDComplementary Medicine Approaches to TMD Pain Management
NCT00066937PHASE2COMPLETEDComparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)
NCT00899717PHASE1/PHASE2COMPLETEDOcclusal Adjustment as Treatment for Chronic Orofacial Pain
NCT02602483PHASE1/PHASE2COMPLETEDExploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).
NCT02794922PHASE2COMPLETEDEffectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain
NCT04557878PHASE2COMPLETEDRole of Liquid Phase Concentrated Growth Factors vs. Hypertonic Dextrose Prolotherapy for Management of Patients With Disc Displacement Without Reduction
NCT04609748PHASE2UNKNOWNComparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.
NCT04724759PHASE2COMPLETEDThe Effect of Opioid-Free Anesthesia in TMJ Surgery
NCT05305833PHASE1/PHASE2UNKNOWNStem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease
NCT05883982PHASE2COMPLETEDIntra-articular I-PRF Injections in Patients With Temporomandibular Joint Dysfunction
NCT00870922PHASE1UNKNOWNEffects of Masseter Manual Therapy on Temporomandibular Dysfunction
NCT01659372PHASE1UNKNOWNLow Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
NCT02202070PHASE1WITHDRAWNBotox for Treatment of TMJ Disorder With Bruxism
NCT03137914PHASE1COMPLETEDNasal Septum Autologous Chondrocytes Transplantation for Condylar Resorption After Orthognathic Surgery
NCT06214637PHASE1UNKNOWNEffectiveness of Melissa Officinalis for the Treatment of Probable Sleep Bruxism in Children and Adolescents
NCT03655275EARLY_PHASE1UNKNOWNEffects of Platelet-rich Plasma Prolotherapy of Temporomandibular Joint Subluxation
NCT03675659EARLY_PHASE1UNKNOWNIntra-articular Magnesium Sulfate for Tmj Dysfunction
NCT03991728Not specifiedRECRUITINGAlloplastic Total Temporomandibular Joint (TMJ) Replacement Registry
NCT04376333Not specifiedACTIVE_NOT_RECRUITINGIndividualized Assessment and Treatment for TMD
NCT05006963Not specifiedRECRUITINGTele-Rehabilitation in Patients With Temporomandibular Dysfunction
NCT05068908Not specifiedRECRUITINGBrain Connectivity Patterns in Chronic Temporomandibular Joint Disorders
NCT05272488Not specifiedRECRUITINGA Combined Treatment of Manual Therapy and Nervous Vagus Stimulation in Patients With Myogenic Temporomandibular Disorders
NCT05317390Not specifiedRECRUITINGClinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
NCT05676827Not specifiedENROLLING_BY_INVITATIONPain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain
NCT05710952Not specifiedRECRUITINGImpact of Orthodontic Treatment on the Temporomandibular Joints (TMJ) Assessed by Modjaw
NCT05754190Not specifiedRECRUITINGAssessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
SALICYLIC ACID45
HYALURONIC ACID42
BENZTROPINE41
GRANISETRON41
LIDOCAINE41
MEPIVACAINE HYDROCHLORIDE41
NIMESULIDE41
NORTRIPTYLINE41
TRAZODONE41
MAGNESIUM31
NEPIDERMIN31
OZONE31
STARCH, CORN31
LUFENURON22
CHEMBL39953801
CHEMBL11659001
CHEMBL409063101
1701

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 67

This page pulls from 67 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot